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Since the discovery of tumor-associated antigens (TAAs), researchers have tried to develop
immune-based anti-cancer therapies. Thanks to their speciﬁcity, monoclonal antibodies
(mAbs) offer the major advantage to induce fewer side effects than those caused by non-
speciﬁc conventional treatments (e.g., chemotherapy, radiotherapy). Passive immunother-
apy bymeans ofmAbs or cytokines has proved efﬁcacy in oncology and validated the use of
immune-based agents as part of anti-cancer treatment options.The next step was to try to
induce an active immune protection aiming to boost own’s host immune defense against
TAAs. Cancer vaccines are thus developed to speciﬁcally induce active immune protection
targeting only tumor cells while preserving normal tissues from a non-speciﬁc toxicity. But,
as most of TAAs are self antigens, an immune tolerance against them exists representing
a barrier to effective vaccination against these oncoproteins. One promising approach to
break this immune tolerance consists in the use of anti-idiotypic (anti-Id) mAbs, so called
Ab2, as antigen surrogates.This vaccination strategy allows also immunization against non-
proteic antigens (such as carbohydrates). In some clinical studies, anti-Id cancer vaccines
indeed induced efﬁcient humoral and/or cellular immune responses associated with clinical
beneﬁt.This review article will focus on recent achievements of anti-Id mAbs use as cancer
vaccines in solid tumors.
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INTRODUCTION
Since the discovery of tumor-associated antigens (TAAs),
researchers have tried to develop immune-based anti-cancer
therapies. Thanks to their speciﬁcity, monoclonal antibodies
(mAbs) offer the major advantage to induce fewer side effects
than those caused by non-speciﬁc conventional treatments (e.g.,
chemotherapy, radiotherapy). Passive immunotherapy by means
of mAbs or cytokines has proved efﬁcacy in oncology and val-
idated the use of immune-based agents as part of anti-cancer
treatment options (Ferrantini et al., 2007; Weiner et al., 2009).
The next step was to try to induce an active immune pro-
tection aiming to boost own’s host immune defense against
TAAs.
Active immunotherapy or vaccination is an antigen (Ag)-
speciﬁc immune-stimulation. It consists in administering an Ag
in the presence of an adjuvant. The role of the adjuvant is to
induce a localized inﬂammatory reaction at the Ag administration
site, making it more immunogenic. This adjuvant effect can be
contained directly in the Ag, when it consists of an attenuated or
dead infectious agent. Indeed, membranes substances (LPS) and
DNA (CpG motifs) of infectious agents are able to activate the
immune system. Currently, the artiﬁcial adjuvant most often used
in vaccine preparations is aluminum hydroxide, while in mice the
Freund’s adjuvant is most used.
In oncology, unlike non-speciﬁc active immunotherapy, the
goal of vaccination is to stimulate a speciﬁc anti-tumor response
targeting a TAA (Foon et al., 1999). The scientiﬁc rationale of
this approach was that the immune effectors generated would be
tumor-speciﬁc while preserving surrounding normal tissues from
a non-speciﬁc toxicity.
The initial orientation of preclinical studies naturally targeted
tumor-speciﬁc neoAgs; either strictly speciﬁc of the tumor (muta-
tions, gene rearrangements, idiotypes), or Ags with expression
restricted to tumor cells. However, as most of TAAs are self
antigens, an immune tolerance against them exists representing
a barrier to effective vaccination against these onco-proteins. One
promising approach to break this immune tolerance consists in
the use of anti-idiotypic (anti-Id) mAbs, so called Ab2, as Ag sur-
rogates. The presence of anti-Id Abs acting as the internal image of
antigen epitopes (Ab2 β) and the ability of anti-Id Abs to modu-
late the immune response have paved theway formany therapeutic
processes in different areas such as autoimmune diseases or cancer
research.
Anti-Id cancer vaccines are able to induce humoral and/or cel-
lular immune responses. Indeed, clinical beneﬁt was observed in
patients enrolled in clinical trials testing anti-Id vaccines in oncol-
ogy, particularly in patients who developed an immune response
against the vaccine itself (Foon et al., 1998, 2000; Samonigg et al.,
1999; Wagner et al., 2001).
This vaccination strategy requires very little equipment and
allows vaccination against Ags from non-protein origin (such as
carbohydrates) that are difﬁcult to purify. Moreover, in preclini-
cal models, the anti-Id Abs are particularly effective in breaking
immune tolerance to certain TAA (Bhattacharya-Chatterjee et al.,
2000; Saha and Chatterjee, 2010; Ladjemi et al., 2011). HAMA
(human anti-mouse antibodies) type responses can be induced
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if the used anti-Id vaccine is from murine origin, but the tech-
niques of Ab humanization (Losman et al., 1999) or the use of fully
human Abs selected for example by phage display, can circumvent
this problem.
In this review article, we will focus on recent achievements of
anti-Id mAbs use as cancer vaccines in solid tumors. A ﬁrst section
will be dedicated to the concept of idiotypy and the anti-Idnetwork
theory ﬁrst described by Jerne (1974). Indeed, according to this
theory, the immune system is organized in Id and anti-Id network
interactions able to regulate the immune response of the host
against a given Ag. This particular feature of the immune system
gave the idea to researchers to use the host’s immune system to
break immune tolerance to oncofetal TAAs. One main advantage
of anti-Id cancer vaccines among other vaccine strategy is their
ability to target Ags from non-protein origin; a special focus will
be given on recent achievements on anti-Id vaccines mimicking
TAA from carbohydrate origin. We will then discuss on the anti-Id
vaccines mimicking TAA from protein origin which are currently
evaluated in clinical development.
THE CONCEPT OF IDIOTYPY
IDIOTYPY AND ANTI-IDIOTYPIC ANTIBODIES
The notion of idiotypy followed the experimental observations
described simultaneously by Kunkel et al. (1963) in humans and
by Oudin and Michel (1963) in rabbits. The idiotype is com-
posed of a set of antigenic determinants or idiotopes (Poskitt
et al., 1991b). The idiotope can be located on the variable light
chain (Pasquali et al., 1987), the heavy chain (Parhami-Seren et al.,
1990) or can result from the interaction of the two chains (Bentley
et al., 1990). Five amino acids may be sufﬁcient to deﬁne a linear
idiotypic determinant (Attanasio et al., 1993). It was estimated that
there were potentially 15–20 idiotopes per Ab molecule (Novotny
et al., 1986), some of them being directly involved in the Ag
binding site while others can be located outside the paratope
(Jerne et al., 1982).
An idiotope is called private if it is expressed by a given spe-
ciﬁc Abs in an individual. Whereas in turn, idiotopes common
to Abs produced by different individuals within a population or
shared byAbs of different speciﬁcity in the same individual, deﬁne
a public idiotope (recurring or cross-reactive idiotope; Poskitt
et al., 1991a). The idiotopes represent one of the two identi-
ﬁed epitope classes for mAbs, the other class being formed by
the allotopes. Unlike allotopes, which are mostly located on the
constant domains of light and heavy chains, idiotopes are found
only in the hypervariable regions of Abs. In addition, idiotopes
are from somatic origin unlike allotopes which are derived from
the germline. The Ab2 anti-Id Abs are directed against idiotopes
present on Abs or on receptors expressed on B lymphocytes; they
can bind to idiotopes located at the site of Ag recognition.
THE IDIOTYPIC NETWORK THEORY
Lindenmann (1973) and Jerne (1974) proposed theories describ-
ing the immune system as a network of interaction of Abs and
lymphocytes. According to this hypothesis, Id and anti-Id net-
work interactions would regulate the immune response of the host
against a given Ag. The network theory is based on the fact that in
the immune system the Ags are mimicked by idiotopes expressed
FIGURE 1 |The idiotypic network. Immunization with a given Ag (green)
generates the production of speciﬁc Abs directed against this Ag, theses
ﬁrst generation of Abs is named Ab1 (black). These Ab1 Abs can generate in
turn the production of a series of anti-Id Abs directed against the Ab1 Abs
and called Ab2. Some of these Ab2 Abs are able to mimic the three
dimensional structure of the starting Ag, the Ab2 β (pink). Immunization
with these Ab2 β Abs may lead to the production of anti-anti-Id Abs (Ab3
Abs) including the Ab1′ Abs (blue) directed against the corresponding initial
Ag recognized by the Ab1.
by Abs and TCR (T cell receptors). According to this network con-
cept (shown schematically in Figure 1) immunization with a given
Agwill generate the production of Abs namedAb1 directed against
this Ag. These Ab1 Abs can generate in turn the production of a
series of anti-Id Abs directed against Ab1 Abs, so called Ab2. Some
of these generated Ab2 Abs is able to mimic the three-dimensional
structure of the starting Ag; the anti-Id Ab2 Abs constituting this
subset are called Ab2 β. They are housed in the paratopes of
Ab1 Abs and are able, when used as immunogens, to induce a
speciﬁc immune response similar to that induced by the initial
mimicked Ag.
Indeed, the β subtype of anti-Id Abs express the internal image
of the Ag recognized by the Ab1 Ab and can therefore be used as
Ag surrogates. Immunization with Ab2 βAbs may lead to the pro-
duction of anti-anti-Id Abs, the Ab3 Abs, part of which recognizes
the starting Ag recognized by the Ab1 Ab. Because of this Ab1-like
reactivity, theAb3Abs are also calledAb1′ Abs to indicate that they
may differ from the Ab1 Ab in their other idiotopes.
There are four subgroups of Ab2 Abs (α, β, γ, and ε) which can
be obtained by immunization with Ab1 Abs:
– Ab2 αAbs are speciﬁc to idiotopes associated with the structure
of the Ab and therefore outside the binding site, their binding
to the Ab1 do not prevent the binding of Ag to the Ab1 (Jerne
et al., 1982).
– Ab2 β Abs recognize an idiotope located in the paratope of the
Ab1Ab. Their binding to theAb1 is naturally inhibited by theAg
they mimic. It is this series of Ab2 Abs that Jerne named “inter-
nal image” (Jerne, 1974) and Lindenmann the “homobodies”
(Lindenmann, 1973). Antigenic determinants of the Ab2 β Abs
are similar in structure to the Ag that binds the Ab1 Abs. These
Ab2 β are able to induce the production of Ab3 Abs which could
bind the original Ag.
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– Ab2 γ Abs recognize idiotopes close to the paratope of the Ab1
Ab and their binding to the Ab1 is inhibited by the binding of
Ag, mainly because of steric hindrance.
– Ab2 ε Abs or “epibodies” have double features as they can bind
both the epitope of the Ag and the idiotope of the Ab directed
against this Ag (the Ab1; Bona et al., 1986).
Of all Abs that can be produced against a given Ab1 Ab, the
one representing the internal image of the Ag would constitute
the best candidate to induce anti-tumoral immune response. In a
preparation of polyclonal Ab2 Abs, only a subset of these Abs is
able tomimic theAg (theAb2 βAbs). Thus, the induced fraction of
Ab3/Ab1′ Abs will be much higher with monoclonal Ab2 β rather
than with a polyclonal Ab2 Ab preparation (Herlyn et al., 1996).
Table 1 summarizes the clinical studies conducted with anti-Id
mAbs as cancer vaccines in solid tumors.
ANTI-IDIOTYPIC VACCINES FOR GLYCOPEPTIDES
CONTAINING TACA
A subset of TAA of carbohydrate nature have been identiﬁed and
called tumor-associated carbohydrate antigens (TACA;Hakomori,
1989). TACA have been described to be expressed speciﬁcally on
tumor cells as compared to normal tissues due to an aberrant gly-
cosylation in tumor cells (Singhal and Hakomori, 1990). Many
of TACA are expressed in fetal tissues and therefore belong to
the group of the so-called oncofetal antigens. Moreover, TACA
play an essential role for metastasis induction and tumor invasive-
ness. Number of TACA have been described, including the blood
group related, mucin related TAA, the gobo series glycosphin-
golipids, and the gangliosides belonging to the group of sialic acid
containing glycosphingolipids (Kobata andAmano,2005; Guo and
Wang, 2009; Cazet et al., 2010).
Gangliosides gained a privileged place as a target for cancer
immunotherapy and recently in a study from the National Can-
cer Institute, 75 representative antigens to be targeted in cancer
therapy were selected; among them four gangliosides GD2, GD3,
fucosylGM1, andN-acetyl-GM3 (Cheever et al., 2009). N-glycolyl
(NGc) gangliosides received particular interest especially with the
anti-Id murine mAb Racotumomab mimicking NGc-containing
gangliosides (ﬁrst known as 1E10 Ab).
1E10 Ab (RACOTUMOMAB)
Racotumomab, ﬁrst known as 1E10 Ab, an anti-Id Ab2 γ murine
mAb was generated after immunization of BALB/c mice with the
P3 Ab1 IgM murine mAb (Perez et al., 2002; Lopez-Requena et al.,
2003; Hernandez et al., 2005). Racotumomab have been used in
several clinical trials and its safety and efﬁcacy were assessed in dif-
ferent tumor localizations: melanoma, breast, and lung cancers.
More recently, there was a speciﬁc interest on pediatric tumors
expressing N-glycolylated gangliosides. A phase I study is indeed
ongoing in patients with pediatric malignancies resistant to con-
ventional treatment (NCT01598454) and the primary outcome
will measure the higher safe dose level for ensuing clinical trials.
Racotumomab has now reached the phase III clinical trials with
possible indications in breast and lung cancer and a possible extent
to pediatric tumors (Fernandez et al., 2010).
Racotumomab clinical evaluation in melanoma
Aclinical trial with aluminumhydroxide-precipitated 1E10Abwas
conducted in 20 patients with advanced melanoma. 1E10 proved
to be safe, well tolerated and able to induce speciﬁc immune
responses against 1E10 itself and Neu-glycolyl-GM3 ganglioside
(Alfonso et al., 2002).
Table 1 | Clinical studies evaluating anti-idiotypic Abs as cancer vaccines in solid tumors.
Anti-Idiotype vaccine Mimicked antigen Tumor type Clinical phase Reference
Racotumomab (1E10) NGc-containing
gangliosides
Breast cancer
Lung cancer
Melanoma?
Pediatric tumors?
I
I/II
Ongoing II/III
I
Ongoing I
Diaz et al. (2003), Guthmann et al. (2006)
Neninger et al. (2007)
Alfonso et al. (2007), Hernandez et al. (2008)
Alfonso et al. (2002)
TriGem GD2 Melanoma I/II Foon et al. (1995, 2000)
MK2-23 HMW-MAA Melanoma I/II Mittelman et al. (1994, 1995)
BR3E4 EpCam Colorectal cancer I Birebent et al. (2001, 2003)
3H1 (CeaVac) CEA Colorectal cancer I/II
III
Foon et al. (1995, 1997)
Chong et al. (2006)
105AD7 CD55 Colorectal cancer I/II Denton et al. (1994), Maxwell-Armstrong et al. (2001)
Maxwell-Armstrong (2002)
11D10 (TriAb) HMGF Breast cancer
Colorectal cancer
Lung cancer
I
II in association with 3H1
II in association with 3H1
Reece et al. (2001, 2003)
Posner et al. (2008)
No data published yet
Abagovomab CA-125 Ovarian cancer I/II
Ongoing II/III
Reinartz et al. (2004), Pﬁsterer et al. (2006)
Sabbatini et al. (2006)
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Racotumomab clinical evaluation in breast cancer
The same formulation of 1E10-Alum used in melanoma was
also evaluated a phase I clinical trial conducted in patients
with stage III/IV breast cancer. Here again 1E10 Ab was safe,
well tolerated and induced speciﬁc humoral immune responses
both against 1E10 itself and NeuGc-GM3 ganglioside (Diaz et al.,
2003). The toxicity and immunogenicity of 1E10 was investigated
in a prolonged vaccination regimen in 19 patients with high-
risk or metastatic breast cancer. 1E10 immunization induced a
humoral response directed against NeuGc-GM3 ganglioside in all
patients; moreover ﬁve patients developed speciﬁcT-cell responses
(Guthmann et al., 2006).
Racotumomab clinical evaluation in lung cancer
A phase I clinical trial was conducted to evaluate the toxicity
and humoral immune response elicited by aluminum hydroxide-
precipitated 1E10 vaccine in nine patients with small cell lung
cancer (SCLC). No evidence of serious adverse effects was found.
Most of the patients developed speciﬁc antibody responses against
both 1E10AbandNeuGc-GM3ganglioside (Neninger et al., 2007).
Although this study was not designed to evaluate the thera-
peutic efﬁcacy of this anti-Id vaccine, a prolonged survival was
observed in several patients. However, due to the small number
of patients enrolled in this clinical trial, it did not allow to make
a correlation between the induced immune response and clinical
outcomes.
1E10/Alum formulation was also assessed in a clinical trial with
stages IIIb and IV non-small cell lung cancer (NSCLC) patients.
No evidence of unexpected or serious adverse effects was reported
(Alfonso et al., 2007). Patients that developed IgG and/or IgM Abs
against NeuGc-GM3 showed longer median survival times (Her-
nandez et al., 2008). Moreover,NeuGc-GM3-speciﬁcAbswere able
to induce complement independent necrosis of tumor cells (Her-
nandez et al., 2011). A phase II randomized trial is now ongoing
in NSCLC patients to conﬁrm the clinical effect of 1E10 MAb vac-
cine and to evaluate the correlationbetween the immune responses
patients’ survival (NCT01240447). A prospective randomized III
study is also running in patients with advanced NSCLC, primary
outcome will measure overall survival (OS; NCT01460472).
TRIGEM Ab
Other clinical trials were performed with anti-Id mAbs mimicking
gangliosides (Lutzky et al., 2002). Different doses of the anti-Id
mAb TriGem mimicking disialoganglioside GD2, which is highly
expressed in melanomas, were administered to patients. An initial
study showed that of the 12 treated patients, one has a complete
response and six showed an arrest of tumor progression (Foon
et al., 1998). A second study conducted on 40 patients showed
a complete response in one patient and stable disease in 12 of
them (Foon et al., 2000). Furthermore, the data obtained suggest
that this anti-Id mAb could have a favorable impact on disease
progression and survival (Foon et al., 2000).
ANTI-IDIOTYPIC VACCINES AS SURROGATES FOR SPECIFIC
ONCOGENE PRODUCTS
We will detail in this section the use of Ab2Abs mimicking speciﬁc
TAA from protein origin as cancer vaccines in different types of
solid tumors: melanoma, lung cancer, colorectal carcinoma, breast
cancer, and ovarian carcinomas.
MELANOMAS
The murine mAb MK2-23 mimicking the TAA HMW-MAA (high
molecular weight-melanoma-associated antigen), was used to
treat patients with advanced melanoma. The authors observed
a regression of metastases (Mittelman et al., 1994) and an increase
in overall survival correlated with the induction of an anti-HMW-
MAA humoral response (Mittelman et al., 1995). Even though
this was a retrospective study, a multivariate analysis showed that
the development of anti-HMW-MAA antibodies was the most
important variable for predicting survival. Wang et al. (2005)
demonstrated that MK2-23 (mimic HMW-MAA)-IL-2 fusion
protein is useful to implement active speciﬁc immunotherapy in
patients with melanoma, because it bypasses the requirement for
KLH conjugation and adjuvant administration.
Other clinical applications of various anti-Id Abs mimicking
the HMW-MAA were conducted in small clinical trials. Among
them, the Melimmune, a mixture of two murine mAbs, has proved
effectiveness to induce Ag-speciﬁc humoral and cellular immune
responses (Saleh et al., 1998). A more recent study has shown that
this vaccine was able to induce speciﬁc cytotoxic T lymphocytes
directed against the HMW-MAA (Murray et al., 2004).
LUNG CANCER
As described above (see Idiotypy and Anti-Idiotypic Antibodies),
the main anti-Id cancer vaccine tested in lung cancer remains
Racotumomab with promising data. Two other anti-Id mAbs
mimicking speciﬁc TAA from protein antigens are also evaluated
in lung cancer patients: 3H1 (CeaVac) and 11D10 (TriAb) mAbs
mimicking, respectively the carcinoembryonic antigen (CEA)
and the human milk fat globule (HMGF) protein. A phase II
study was conducted with 3H1 and 11D10 anti-Id mAbs in
patients with completely resected Stage II and Stage IIIA NSCLC
(NCT00006470). The objectives were the evaluation of toxicity,
humoral and cellular immune responses, and to determine the
progression-free survival (PFS) and OS in theses patients; results
of this study are not published yet.
COLORECTAL CANCER
During the past 20 years, studies on the use of anti-Id Abs have
focused on three main tumor Ags (i) the epithelial cell adhesion
molecule (EpCAM) associated with colorectal cancer (CRC), also
known as GA733, CO17-1A, KS-14, or KSA, (ii) the CD55, also
known as decay-accelerating factor (DAF) involved in the regu-
lation of the complement cascade, and (iii) the CEA known for
its particularly strong expression in 95% of CRC, 70% of lung
adenocarcinomas, and 50% of breast cancers.
BR3E4
BR3E4, an Ab2 anti-Id mAb, was produced in rats against the
murine mAb CO17-1A (Ab1; Herlyn et al., 1987; Maruyama et al.,
2000). In a phase I clinical trial, BR3E4 was administered to 45
patients with CRC as intact IgG or as F(ab′)2 coupled to KLH
(Birebent et al., 2001). This study demonstrated that there was
a trend for the KLH group to induce higher immune response
rates (18/21 and 5/15 patients with anti-anti-Id Abs and T cells,
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respectively) as compared to the groupof patients immunizedwith
the intact IgG (15/23 and 3/15 patients positive). However, clinical
responses were rare as this study was undergone on stage IV CRC
patients with liver metastasis (Birebent et al., 2001, 2003).
3H1 (CeaVac)
An anti-Id murine Ab2 mAb, called 3H1 or CeaVac, mimicking
an epitope of CEA was developed and very early suggested to be
a potential cancer vaccine in patients with CEA-positive tumors
(Bhattacharya-Chatterjee et al., 1990).
In a ﬁrst clinical trial, the safety and immunogenicity of dif-
ferent doses (1, 2, or 4 mg) of aluminum hydroxide-precipitated
anti-Id mAb were evaluated in 12 patients with advanced CRC
(Foon et al., 1995). The vaccine was safe and well tolerated. More-
over, 3H1 was able to break immune tolerance to CEA in these
patients with CEA-positive tumors (Foon et al., 1995). In fact, 9
of 12 patients developed anti-3H1 humoral responses and more
interestingly all nine patients generated speciﬁc anti-CEAantibody
responses. Moreover, 7 of 12 patients demonstrated idiotype-
speciﬁc T cell proliferative responses and four also showed T cell
proliferation to CEA (Foon et al., 1995). This 3H1 formulation
was evaluated in a phase Ib trial in 24 patients with advanced
CEA-positive CRC (Foon et al., 1997). The safety and immuno-
genicity of the vaccine conﬁrmed the previous study. Even though
the clinical beneﬁt of 3H1 vaccine could not be proved in this
study, since overall median survival (11.3 months) was compara-
ble to other phase II data with advanced CRC patients treated
with a variety of chemotherapy agents, including irinotecan,
3H1 vaccine promisingly induced considerably less toxicity
(Foon et al., 1997).
3H1 anti-Id mAb is now evaluated in phase II and III clinical
trials either alone or in combination with the anti-Id mAb 11D10
(TriAb) mimicking HMGF protein.
A phase III controlled randomized clinical trial was conducted
on 630 patients with untreated metastatic CRC (Chong et al.,
2006). The patients received 5-ﬂuorouracil (5-FU) and leucovorin
(LV) plus either 3H1 or placebo. The addition of 3H1 to 5-FU
and LV did not result in increased toxicity but was not shown to
improve overall patient outcomes (Chong et al., 2006). Anti-CEA
antibody responses were observed in 70% of patients treated with
3H1; these patients had improved survival (median survival not
reached) as compared to patients with a negative CEA response
(median survival: 8.3 months; Chong et al., 2006).
The data of the ﬁrst phase II clinical trial evaluating the com-
bination of 3H1 and 11D10 anti-Id mAbs in patients with CRC
metastatic to the liver were published (Posner et al., 2008). Vacci-
nations consisted of four biweekly treatments of 3H1 and 11D10,
then monthly for 2 years, then on every other month for 3 years.
The primary endpoint of the study was to investigate the propor-
tion of patients recurrence-free at 2 years. The vaccine was well
tolerated but didnot improve 2-year recurrence-free survivalwhen
compared with the expected value of 40% reported for hepatic
resection alone (Posner et al., 2008).
105AD7
The cancer vaccine 105AD7 is a human anti-Id mAb that mimics
the CD55 TAA on CRC cells. This anti-Id mAb was produced by
fusion of a mouse/human heteromyeloma cell line with lympho-
cytes from a patient previously injected with mouse mAb 791T/36
for tumor immunoscintigraphy (Austin et al., 1989). Phase I stud-
ies in patients with advanced CRC demonstrated the safety and the
immunogenicity of 105AD7 anti-Id mAb (reviewed by Maxwell-
Armstrong, 2002). Immunization with 105AD7 induced T-cell
immune responses in 83% of patients with a permissive haplo-
type (Durrant et al., 2000). In a phase I clinical trial, the cancer
vaccine induced an increase in median-free survival for immu-
nized patients versus unimmunized patients (12 vs. 4 months
respectively; Denton et al., 1994). These resultswere not conﬁrmed
in a randomized double-blind phase II survival study (Maxwell-
Armstrong et al., 2001). The reasons for lack of efﬁcacy are unclear
but with half of patients receiving only one or two doses of
105AD7, it seems to be insufﬁcient to improve survival. A fur-
ther survival analysis was then conducted but at 2-year follow-up,
the vaccine did not improved OS (Maxwell-Armstrong, 2002).
BREAST CANCER
Studies on the use of anti-IdAbs as cancer vaccines in breast cancer
have focused on three main tumor Ags (i) the HMGF protein with
11D10 (TriAb), (ii) gangliosides with 1E10 (Racotumomab), and
(iii) HER2 receptor (still in preclinical development).
The use of 11 D10 was evaluated in conjunction with autolo-
gous stem cell transplantation in patients with metastatic breast
cancer (Reece et al., 2001, 2003). Immunization with 11D10 anti-
Id mAb induced speciﬁc humoral and T-cell immune responses in
the majority of patients (Reece et al., 2003). Moreover, patients
with the most vigorous immune responses had a signiﬁcant
improvement in PFS (Reece et al., 2001)
The data on the use of anti-Id Abs mimicking HER2 as can-
cer vaccines for breast cancers are preliminary and still in the
preclinical development.
Baral et al. (2001) have immunized C57BL/6 mice with the
murine anti-Id mAb 520C9-6b mimicking a human epitope of
HER2 Ag. The results of this preclinical study have shown that
immunization with 520C9-6b could induce anti-HER2 Abs in
vaccinated mice suggesting that this antibody could be used
as a surrogate Ag of HER2 to induce a humoral and cellular
response in patients with HER2-positive tumors. More recently,
the same group developed and characterized a murine mAb 6D12,
which mimics a speciﬁc epitope of HER2, the one recognized by
trastuzumab. Immunization of C57BL/6 with 6D12 in combina-
tion with the adjuvant vaccine QS21, has led to the development
of speciﬁc humoral responses. In addition, mice immunized with
6D12 were protected against a syngeneic graft of a lethal dose
of the same cells (Mohanty et al., 2007; Pal et al., 2007). More-
over, immunization of transgenic mice tolerant to HER2 Ag with
6D12-pulsed dendritic cells (DC) could reverse Her-2/neu unre-
sponsiveness and result in the induction of HER2/neu-speciﬁc
humoral and cellular immune responses and protection against
tumors expressing HER2/neu (Saha and Chatterjee, 2010).
Two human scFv fragments, named 40 and 69, and a llama anti-
Id single domain antibody (sdAb), named VHH 1HE, capable of
mimicking the epitope of HER2 Ag recognized by trastuzumab
were selected by phage display. These anti-Id scFv and VHH frag-
ments induced an anti-HER2 antibody response in BALB/c mice
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(Coelho et al., 2004; Alvarez-Rueda et al., 2009). Moreover, vac-
cination with anti-Id scFv fragments was able to reverse HER2
immunological tolerance and to protect HER2-tolerant mice from
developing spontaneous mammary tumors (Ladjemi et al., 2011).
Such vaccination elicited speciﬁc humoral and T-cell responses
(Ladjemi et al., 2011).
OVARIAN CANCERS
The use of the anti-IdmAbACA-125 (orAbagovomab)mimicking
the tumor antigenCA-125 (cancerAg125), over-expressed inovar-
ian tumors has been reported in several clinical trials. It has been
shown, in preclinical and phase I clinical studies, thatAbagovomab
could induce humoral and cellular immune responses against CA-
125 without the occurrence of toxicity related to this treatment
(Wagner et al., 2001). In another phase Ib/II study, 119 patients
with advanced ovarian cancer received 10 injections of Abagov-
omab; a CA125-speciﬁc humoral response was induced in 50%
of patients. A positive correlation was also observed between the
development of a speciﬁc humoral response and OS (Reinartz
et al., 2004). It should be noted that preclinical data suggest that
use of a fusion protein formed by the Abagovomab and IL-
6 may induce a more robust CA125-speciﬁc humoral response
(Reinartz et al., 2003). Other phase I clinical trials evaluated
Abagovomab in recurrent ovarian cancer (Pﬁsterer et al., 2006)
or primary peritoneal tumors (Sabbatini et al., 2006) and con-
ﬁrmed the encouraging results obtained with this anti-Id mAb.
The efﬁcacy of Abagovomab is currently evaluated in a phase
III randomized, double-blind, placebo-controlled clinical trial for
patients in complete remission after a stage III-IV CA-125 positive
ovarian, fallopian tube or primary peritoneal cancer (Grisham
et al., 2011; Pﬁsterer et al., 2011). The primary outcome will
measure recurrence-free survival; safety, time course of immune
response, and OS will be measured as secondary outcomes.
Preliminary immunogenicity data for weeks 10 and 22 showed
that 68 and 69% of patients were positive for Ab3 Abs (Grisham
et al., 2011).
CONCLUSION
Immunotherapy has nowadays an important place in oncology
treatment. The major advantage of this type of strategy is the spe-
ciﬁc targeting of tumor Ags, which implies less toxicity and side
effects compared to conventional therapies. Today, 12 therapeutic
Abs were approved by FDA for the treatment of cancers. Neverthe-
less, the highnumber of patients treated by therapeuticAbs and the
experience taken from the several clinical trials conducted in this
ﬁeld have pointed two major problems currently facing Ab-based
immunotherapy: (i) the development of drug resistance by tumor
cells and (ii) the need of repeated injections required to achieve a
lasting therapeutic effect, which implies a high cost for this type
of therapy. Cell-based immune therapy faces with technical difﬁ-
culties as it is still hard to establish a cell-based immunotherapy
because of the individualization of the procedure and technical
conditions of relatively complex ex vivo culture. However, the
technological progress that the sector is currently experiencing
lets consider the cell-based immune therapy as a promising future
therapeutic strategy.
Active immunotherapy or vaccination offers the main advan-
tage of requiring fewer injections than for therapeutic Abs. More
importantly, vaccines offer the establishment, theoretically, of a
memory response that persists after the end of treatment and
could prevent the occurrence of relapses. Nevertheless, this strat-
egy is still in preclinical and clinical development. This delay, as
compared to other immunotherapy strategies, could be explained
at least in part by the fact that clinical trials currently conducted
are not adequate with a vaccination strategy. Indeed, vaccines are
tested in patients with advanced stages of disease with immune
system already weakened by many cycles of chemotherapy already
undergone. This implies that the clinical beneﬁt of this type of
therapeutic strategy is even more difﬁcult to demonstrate. How-
ever, the increasing interest for anti-tumoral vaccination could
accelerate the development of cancer vaccines and increase the
number of vaccine candidates to be tested which implies a larger
number of clinical trials and thus give rise ultimately to com-
mercialization of vaccines cancer. In addition, with the recent
approval of the ﬁrst cancer vaccine sipuleucel-T by the FDA in
2010 for metastatic hormone-refractory prostate cancer, cancer
vaccines are entering a new promising era. In fact, sipuleucel-T
increased OS in a randomized phase III trial conducted in patients
with advanced prostate cancer (Higano et al., 2009, 2010).
Overall, research on anti-Id cancer vaccines has greatly evolved
over the past decades even though there is yet a lot to do in this
ﬁeld. This vaccination strategy requires very little equipment and
allows vaccination against Ags from non-protein origin (such as
carbohydrates). Anti-Id cancer vaccines present the advantage to
address to the entire population (regardless of HLA) as compared
to protein or peptide-based vaccines. Moreover, they are capable
of inducing an immune response more robust, at least in theory,
since it is formed of humoral but also cellular component. These
advantages allow foreseeing a bright future for this type of vac-
cine strategy. However, although most of anti-Id cancer vaccines
proved safety, tolerability, and immunogenicity, the clinical beneﬁt
remains to be proved. This proof of clinical beneﬁt will be per-
haps provided by the promising anti-Id mAbs Racotumomab and
Abagovomab, which are now evaluated in phase III clinical trials.
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